🔴 Beam Therapeutics is trading 4% down today as profit-taking extends multi-day slide

Beam Therapeutics is trading 4% down at $26.42 as profit-taking and fading momentum continue to weigh on the stock during an extended pullback.

• The decline marks eight consecutive negative sessions, representing a cumulative drop of approximately 27% from recent levels.
• The downward move follows a strong six-month rally fueled by positive FDA and clinical trial headlines, with no fresh company-specific setbacks reported today.